Work

Beyond peptides and mAbs—current status and future perspectives for biotherapeutics with novel constructs

Year: 2015

Type: review

Abstract: Biotherapeutics are attractive anti-cancer agents due to their high specificity and limited toxicity compared to conventional small molecules. Antibodies are widely used in cancer therapy, either directly or conjugated to a cytotoxic payload. Peptide therapies, though not as prevalent, have been utilized in hormonal therapy and imaging. The limitations associated with unmodified forms of both types of biotherapeutics have led to the design and development of novel structures, which incorporate key features and structures that have improved the molecules' abilities to bind to tumor targets, avoid degradation, and exhibit favorable pharmacokinetics. In this review, we highlight the current status of monoclonal antibodies and peptides, and provide a perspective on the future of biotherapeutics using novel constructs.

Source: The Journal of Clinical Pharmacology

DOI: 10.1002/jcph.407

Authors: Dalal AlDeghaither, Brandon G. Smaglo, Louis M. Weiner

Institutions: Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute